Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma

References

• Surveillance Research Program NCI. SEER*Explorer: an interactive website for SEER cancer statistics; 2020. Available from: https://seer.cancer.gov/explorer/. Accessed May 10, 2020.
   Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.can-14-0155
   PubMed Web of Science ®Google Scholar
• Müller PC, Frey MC, Ruzza CM, et al. Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence. Pharmacology. 2020;1–11. doi:10.1159/000510343.
   PubMed Web of Science ®Google Scholar
• Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–347. doi:10.1097/sla.0000000000002753
   PubMed Web of Science ®Google Scholar
• Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer. Ann Surg. 2016;264(3):457–463. doi:10.1097/sla.0000000000001850
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Algül H, Goekkurt E, et al. Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): final results of a multicenter randomised Phase II AIO trial. Ann Oncol. 2019;30(Supplement_5):v253. doi:10.1093/annonc/mdz247
   Google Scholar
• Michelakos T, Pergolini I, Castillo CF-D, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733–740. doi:10.1097/sla.0000000000002600
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma. JAMA Oncol. 2018;4(7):963. doi:10.1001/jamaoncol.2018.0329
   PubMed Web of Science ®Google Scholar
• Jang J-Y, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer. Ann Surg. 2018;268(2):215–222. doi:10.1097/sla.0000000000002705
   PubMed Web of Science ®Google Scholar
• Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–1773. doi:10.1200/JCO.19.02274
   PubMed Web of Science ®Google Scholar
• Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49(2):190–194. doi:10.1093/jjco/hyy190
   PubMed Web of Science ®Google Scholar
• Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38(15_suppl):4505. doi:10.1200/JCO.2020.38.15_suppl.4505
   Web of Science ®Google Scholar
• Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. doi:10.1371/journal.pmed.1000267
   PubMed Web of Science ®Google Scholar
• Mellon EA, Jin WH, Frakes JM, et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncologica. 2017;56(3):391–397. doi:10.1080/0284186x.2016.1256497
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label Phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. doi:10.1016/S0140-6736(17)31601-X
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–1251. doi:10.1016/S1470-2045(19)30388-2
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial. Ann Oncol. 2013;24(1):75–83. doi:10.1093/annonc/mds213
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. doi:10.1200/jco.2016.67.6601
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/nejmoa1809064
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–2379. doi:10.1200/jco.20.00793
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi:10.1158/1078-0432.ccr-18-4070
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/jco.19.02105
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves pembrolizumab for adults and children with TMB-H solid tumors; 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors. Accessed May 11, 2021.
   Google Scholar
• Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):3217–3230. doi:10.1200/jco.20.01364
   PubMed Web of Science ®Google Scholar
• Network NCC. Pancreatic adenocarcinoma (version 1.2020), 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic_blocks.pdf. Accessed August 10, 2020.
   Google Scholar
• Perri G, Prakash L, Wang H, et al. Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer. Ann Surg. 2021;273(4):806–813. doi:10.1097/SLA.0000000000003442
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang Y-J, Piha-Paul SA, et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327. doi:10.1200/jco.2018.78.2276
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833. doi:10.1097/cji.0b013e3181eec14c
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Oh D-Y, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma. JAMA Oncol. 2019;5(10):1431. doi:10.1001/jamaoncol.2019.1588
   PubMed Web of Science ®Google Scholar
• Kamath SD, Kalyan A, Kircher S, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist. 2020;25(5):2. doi:10.1634/theoncologist.2019-0473
   Web of Science ®Google Scholar
• Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020;19(1):32. doi:10.1186/s12943-020-01151-3
   PubMed Web of Science ®Google Scholar
• Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2020;6. doi:10.3389/fmolb.2019.00160.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol Res. 2017;5(11):978–991. doi:10.1158/2326-6066.cir-16-0322
   PubMed Web of Science ®Google Scholar
• Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. OncoImmunology. 2015;4(3):e976052. doi:10.4161/2162402x.2014.976052
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965–2970. doi:10.1158/1055-9965.epi-14-0654
   PubMed Web of Science ®Google Scholar
• Eso Y, Seno H. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therap Adv Gastroenterol. 2020;13:175628482094877. doi:10.1177/1756284820948773
   Web of Science ®Google Scholar
• Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0361-7
   Google Scholar
• Wang Y, Kim TH, Fouladdel S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep. 2019;9(1). doi:10.1038/s41598-018-36096-7
   Google Scholar
• Azad A, Yin Lim S, D’Costa Z, et al. PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017;9(2):167–180. doi:10.15252/emmm.201606674
   PubMed Web of Science ®Google Scholar
• Cellini F, Arcelli A, Simoni N, et al. Basics and frontiers on pancreatic cancer for radiation oncology: target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines. Cancers. 2020;12(7):1729. doi:10.3390/cancers12071729
   PubMed Web of Science ®Google Scholar
• Talimogene laherparepvec and radiation therapy in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery; 2021. Available from: https://ClinicalTrials.gov/show/NCT02923778. Accessed May 11, 2021.
   Google Scholar
• Duffy AG, Makarova-Rusher OV, Kleiner DE, et al. A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer. J Clin Oncol. 2017;35(15_suppl):e15786. doi:10.1200/JCO.2017.35.15_suppl.e15786
   Google Scholar
• Bar-Sagi D, Knelson EH, Sequist LV. A bright future for KRAS inhibitors. Nat Cancer. 2020;1(1):25–27. doi:10.1038/s43018-019-0016-8
   PubMedGoogle Scholar
• Fakih M, Desai J, Kuboki Y, et al. CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer. J Clin Oncol. 2020;38(15_suppl):4018. doi:10.1200/JCO.2020.38.15_suppl.4018
   Web of Science ®Google Scholar
• Ward AB, Keeton AB, Chen X, et al. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm. 2020;1(2):121–128. doi:10.1002/mco2.10
   PubMedGoogle Scholar